Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Partners hit as Reata ends PhIII BEACON trial with bardoxolone in CKD

This article was originally published in Scrip

Executive Summary

Abbott investors sent the company's stock down for the second day in a row after its partner Reata Pharmaceuticals said on 18 October that the private firm had terminated the Phase III BEACON clinical trial evaluating its antioxidant inflammation modulator (AIM) bardoxolone methyl (RTA 402) in the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes.

You may also be interested in...



Outlook For Reata's Bardoxolone Improves With Phase II Updates

Latest data support moving bardoxolone into Phase III for autosomal dominant polycystic kidney disease (ADPKD).

IPO Update: Three More Biotechs Squeeze Through The Window

What's the best metaphor for the past two weeks of US biotechnology initial public offerings? That would be a sharp intake of air through the teeth – the sound you make when you see someone do something really painful.

Upgraded Paige Suite Gains CE-IVD and UKCA Marks

Paige’s AI has obtained CE-IVD and UKCA marks, allowing the launch of a breakthrough product that can spot biomarkers from images.

Topics

Related Companies

UsernamePublicRestriction

Register

SC019164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel